Seelos Therapeutics, Inc. (SEELQ) - Total Assets
Based on the latest financial reports, Seelos Therapeutics, Inc. (SEELQ) holds total assets worth $2.38 Million USD as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Seelos Therapeutics, Inc. to assess how comfortably operating cash covers total debt obligations.
Seelos Therapeutics, Inc. - Total Assets Trend (2020–2023)
This chart illustrates how Seelos Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See SEELQ net asset value for net asset value and shareholders' equity analysis.
Seelos Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Seelos Therapeutics, Inc.'s total assets of $2.38 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.3% |
| Accounts Receivable | $763.00K | 14.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Seelos Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Seelos Therapeutics, Inc. (SEELQ) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seelos Therapeutics, Inc.'s current assets represent 99.7% of total assets in 2023, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2023, down from 89.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
Seelos Therapeutics, Inc. Competitors by Total Assets
Key competitors of Seelos Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Seelos Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.21 | 0.21 |
| Quick Ratio | 0.08 | 0.21 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-28.18 Million | $-44.27 Million | $-44.27 Million |
Seelos Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Seelos Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -76.2% |
| Total Assets | $5.42 Million |
| Market Capitalization | $58.00 USD |
Valuation Analysis
Below Book Valuation: The market values Seelos Therapeutics, Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Seelos Therapeutics, Inc.'s assets decreased by 76.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Seelos Therapeutics, Inc. (2020–2023)
The table below shows the annual total assets of Seelos Therapeutics, Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $5.42 Million | -76.18% |
| 2022-12-31 | $22.75 Million | -72.76% |
| 2021-12-31 | $83.50 Million | +377.31% |
| 2020-12-31 | $17.49 Million | -- |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more